Home - Australian Pharmacist

King of poisons or ‘magic bullet’?

Thea Cowie - 24 May 2018

Opinion

A potent poison purportedly behind the death of a king, arsenic has also served numerous, less-sinister, medicinal purposes. In fact, the terms ‘magic bullet’ and...

Ensuring patients’ medical data is secure

David Barbeler - 21 January 2019

Industry

The rollout of My Health Record has raised questions surrounding the security of medical data. What measures must be taken in pharmacies to preserve...

The power of compassion in clinical pharmacy

Thea Cowie - 4 June 2018

People

Yong Deng is a Grade 1 clinical pharmacist at Monash Health and one of the founders of South Sudanese Australian Youth United (SSAYU), a...

Data collection payments to stop

Ann Winkle MPS - 19 February 2020

Industry

6CPA programs

Hay fever affects sleep, relationships and careers — so why don’t...

Mikaela Dery - 5 November 2018

Clinical

Experts are urging allergic rhinitis (hay fever) sufferers to seek the help of pharmacists, following a recent poll showing hay fever to be the...

PSA’s national guidelines on MHR

Thea Cowie - 24 April 2018

Industry

It's been described as a 'game changer' for pharmacists and now there's a practical guide to unlocking the potential of My Health Record. PSA's new...

1...281282283...331 Page 282 of 331

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

A system under strain

One-stop medicinal cannabis shops

Profit over patients

Driving under the influence

Misleading marketing

A lack of evidence

What next?

References

What is diphtheria?

What are the symptoms?

How dangerous is the disease?

Was it once eradicated in Australia?

Why has there been a resurgence?

Can diphtheria be treated?

Who is most at risk?

What are the risks of an outbreak here?

How often are booster doses required?

What can pharmacists do?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

A system under strain

One-stop medicinal cannabis shops

Profit over patients

Driving under the influence

Misleading marketing

A lack of evidence

What next?

References

What is diphtheria?

What are the symptoms?

How dangerous is the disease?

Was it once eradicated in Australia?

Why has there been a resurgence?

Can diphtheria be treated?

Who is most at risk?

What are the risks of an outbreak here?

How often are booster doses required?

What can pharmacists do?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions